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Tom Tomich (University of California-Davis): Martina, you talked about the huge regula-
tory hurdles. Carl talked earlier about the notion of risk and benefit, and so my question 
has two parts. who credibly do those risk/benefit balancing studies and how are they 
communicated to the public? 
Martina Newell-McGloughlin: The regulations in this country are at least somewhat ra-
tional. The three main agencies that cover biotechnology are the ones you might expect. 
The USDa, where most of the deregulation process is gone through, was one of the 
first to determine that, in fact, they didn’t have to introduce any new regulations—that 
those on the books were sufficient—but, that they would need to develop guidelines that 
allowed people to go through this process of determining if something had, or could 
reach, deregulation status, that is generally regarded as safe. The other agencies then are 
the ePa, looking at the environmental impact, and the fDa, where there is actually a 
voluntary consultation. You would be pretty stupid not to consult with them, so every 
company does.
Tomich: But my question wasn’t who regulates. In order to look at the risk/benefit you 
would actually have to look at the agricultural, environmental and health—
Newell-McGloughlin: all they are looking at is the risk. There is no focus—and, in fact, that 
is one of the points I made here—there is no focus at all, anywhere, on the benefits.
Tomich: So in academia? why doesn’t somebody do it?
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Newell-McGloughlin: It’s not part of the process. we do it. absolutely the benefit com-
ponent is done. nobody would be doing any of the work that I told you about because 
most of that is still sitting in the lab. It’s all aspirational. one would hope that this will 
get through the deregulation process. But in some areas—europe—it appears to be going 
backwards. There is such a focus on the precautionary principle that, in fact, it would 
probably be illegal, if you are going to interpret it to its fullest extent; it would be illegal 
to do anything for the first time. How ridiculous is that? So you are actually forced to 
depend on older, less-safe technologies. I’ll give you an example from a personal heritage 
perspective. Growing up, we used to use a particular fungicide called bluestone, copper 
sulfate, to control late blight in potato. now BaSf has developed a potato with resis-
tance to Phytophthora infestans by taking two genes from another potato, a solanaceous 
species in Mexico, and introducing them and getting complete resistance, and stable 
resistance—which is often hard with our genes—against late-blight disease. I thought 
they would be going with open arms in Ireland to get them. Instead they pulled out the 
plug, because they were told by certain groups that these were toxic. They failed under 
the precautionary principle. The alternative is using copper sulfate, which has organic 
approval because it is considered “natural.” This is a complete false dichotomy, as Carl said 
earlier, this notion of natural and non-natural. The focus should be on good and effica-
cious versus non-good, or less good. with the precautionary principle, people are stuck, 
depending on older, less-safe, less-efficacious and—for sure—less sustainable production 
systems. So, when you are in that sort of situation and there is no focus on efficacy and 
benefits, it is really difficult to get past it. 
Barbara Schneeman (US Food and Drug Administration): I just wanted to comment on 
the risk-benefit paradigm because—at least coming from the fDa perspective—to be on 
the market, foods have to be safe. They don’t have to prove a benefit to be on the market 
and on the food side of fDa you actually, in fact, separate the risk-benefit construct, 
because, to be on the market, you have to be safe. You don’t have to prove a benefit. It’s 
really in drugs that you get into a risk-benefit balance. now I think, Martina, you are 
trying to also address environmental benefits, but, at the end of the day, you still have to 
consider, “Is the food safe?”
Newell-McGloughlin: Yes. That’s what I said, it’s all risk in that respect. now, of course, 
we could run ourselves into a real problem here if we are suggesting proving efficacy. now 
you are up against drugs. You are now looking at $ billion to $ billion dollars to take 
it to market, if we are going to be looking at a pharmaceutical effect from a bioactive 
component. It’s a very finely balanced line we need to walk here, because we don’t want 
to have approval purely based on demonstrating efficacy.
Michael Jacobson (Center for Science in the Public Interest): Martina, on your last slide 
you listed a bunch of challenges. I would think a key challenge is finding something that 
consumers find useful, and I haven’t seen anything that is anywhere near the pipeline. 
Monsanto has come to me and said, “Do you have ideas of something that might be use-
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ful?” Until you get something obviously useful, like taste, consumers will say, “why should 
we eat the genetically modified wheat or canola oil or whatever?” Do you have ideas?
Newell-McGloughlin: The short-chain fructans is a particular example there, where they 
actually taste sweet. Cynthia Kenyon, looking at genes that increase longevity, found most 
of them are actually sensate. our primitive ancestors, the worms, et cetera, when sensing 
the environment, are actually responding to sugars. She has completely cut sugar from her 
diet and she looks good. The idea with the short-chain fructans is that you can, potentially, 
eliminate, high fructose corn syrup, sucrose and fructose from your diet.
Jacobson: How many years away do you think those are from market?
Newell-McGloughlin: That’s the problem. It’s sitting in Dr. Coop’s lab because he knows 
that to get it through eU approval would be an enormous hurdle; the activation energy 
is so high, especially in europe. rather interestingly, on the animal side—since I talked 
about using plants as factories—the very first approval of using a genetically engineered 
animal to produce pharmaceuticals in its milk was given in europe. There was a whole 
different view here, because, in fact, it was a pharmaceutical, an anti-thrombin agent at 
that point in time. It was a full year afterwards that the US approved it because, rather 
interestingly enough, the US was focusing on the health of the animal as well—this 
sounds counterintuitive—whereas europe was looking at the safety and efficacy of the 
anti-thrombin drug itself, atryn. But that’s just an aside. The issue is the cost, the time, 
the enormous effort to get it through.
Michael Kahn (Washington State University): I’ve come to the conclusion that many people 
oppose GMos less from the risk of the GMo itself than from the companies that are trying 
to put them out. we are in a situation now, which is ironic, where the Monsantos have 
figured that they can make enough money by pushing these things through the regula-
tory process, that they are willing to go ahead and do it, whereas, as you have indicated, 
small companies, and particularly producers of minor crop fruits and vegetables that we 
have been talking about as being nutritious here, are not going to be able to afford it. 
The whole market of those crops, in many cases, is less than what people are estimating 
for the certification. and so, instead of blocking monopolistic properties of Monsantos, 
the current regulatory situation is actually promoting them.
Newell-McGloughlin: for sure you could debate that and I absolutely agree, small com-
modities have a much harder row to hoe. The potato is a perfect example. again it was 
produced by a big company, but, in fact, I heard from one individual who blithely told 
me, “we are not allowing that BaSf product in here.” no focus on the notion that you 
are going to reduce the actual amount of chemical used to control it. The big focus was 
that it was intellectual property owned by BaSf. But the reason PIPra exists actually is 
to focus on small commodity groups, which is a huge issue, of course, in California. we 
produce about 50 commodities. So it is much, much more difficult for us to go through 
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the process of deregulation because of the cost of the biosafety hurdle. But Monsanto will 
tell you they find it a total pain too. They were talking specifically about new abiotic-
stress-resistant strains that they are bringing in, using transcription factor modifications. 
But they are back to square one with the USDa and ePa. of course, needless to say, 
they have deeper pockets than we do in academia, so it’s definitely an easier process for 
them than it is for us. and there have been very few products, in fact probably the only 
really strong product that has come out of academia is the ringspot-resistant papaya, 
from Dennis Gonsalves in Hawaii, and most of that work was done when he was at 
Cornell. There is no natural resistance against this virus, so it doesn’t matter how good 
your marker-assisted selection process is. If the genes aren’t in there you can’t breed them 
in, no matter how much you try. So he took a copy of the coat protein from the virus, 
stuck it in there and it worked through the process that got the nobel Prize, but not for 
him, called rna interference, which confers protection against ring spot. In addition, 
it helps organic farmers, who grow rings of biotech crop around their non-engineered 
varieties to reduce the viral reservoir. However, back to your point, that was one of the 
few products that has gone through the process from an academic situation. all of the 
others have come from companies. 
Alan McHughen (University of California-Riverside): Thank you Martina—enlightening 
and entertaining as usual. Just a quick comment on where are the products of benefit 
to consumers. If you ask consumers whether they would support a product, a food, a 
crop that could be developed with fewer pesticides, they would say, “Yeah, that is a good 
product. I’ll support that and I’ll even pay extra for it.” So that is a benefit to consumers. 
They might not be aware of it directly. and, secondly, several recent economic studies, 
including one from our own national research Council of the national academies, 
have resulted in publication of economic analyses of the benefits of biotechnology to US 
agriculture, and determined there is a huge economic return that is not being captured 
exclusively by companies or even by farmers, but by society at large. and that means in 
practical terms you are paying less for your food because of agricultural biotechnology. 
That’s something that consumers can relate to, but they are generally not aware of it.
McGloughlin: They’re not aware of it. It’s opaque to them.
